AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32705177 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAS-PCR for TPMT*3 mutations detection
Number of subjects: 226
Study 32705177 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA sequencing of TPMT*3C MT heterozygotes
Number of subjects: 226
Study 33966464 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularized optimization problem based on a plug-in image-denoising function using a randomized second order method.
Number of subjects: 0
Study 32857315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.46 mg (group A, n = 20)
Number of subjects: 100
Study 32857315 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily for 17 days + ozanimod 0.46 mg on day 4 (group B, n = 20)
Number of subjects: 100
Study 32857315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg (group C, n = 20)
Number of subjects: 100
Study 32857315 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 17 days + ozanimod 0.92 mg on day 4 (group D, n = 20)
Number of subjects: 100
Study 32857315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for 21 days + ozanimod 0.92 mg on day 8 (group E, n = 20)
Number of subjects: 100
Study 33561819 — intervention group
Group type: EXPERIMENTAL
Intervention: PAUSE
Number of subjects: 26
Study 33561819 — intervention group
Group type: COMPARATOR
Intervention: REBOUND
Number of subjects: 26
Study 32668845 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment for childhood cancer, details on dosage and duration not available.
Number of subjects: 0
Study 32668845 — intervention group
Group type: COMPARATOR
Intervention: International randomized controlled trials for childhood cancer, details on specific interventions not available.
Number of subjects: 0
Study 34612612 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% complex motor imagery
Number of subjects: 88
Study 34612612 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% simple motor imagery
Number of subjects: 88
Study 34612612 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex tasks
Number of subjects: 88
Study 34612612 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of imagery (50% vs. 75%)
Number of subjects: 88
Study 34612612 — intervention group
Group type: COMPARATOR
Intervention: Task complexity and rate of imagery
Number of subjects: 88
Study 33055544 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (mint-flavored sugar-free gum) for 20 minutes every 2 hours until colonoscopy after consuming 2 L of polyethylene glycol solution
Number of subjects: 60
Study 33055544 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol solution (control group)
Number of subjects: 60
Study 33782936 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric calf muscle exercise with knee fully extended
Number of subjects: 11
Study 33782936 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric calf muscle exercise with knee flexed to 80°
Number of subjects: 11
Study 33782936 — intervention group
Group type: COMPARATOR
Intervention: Comparison of knee extension vs knee flexion
Number of subjects: 11
Study 32762708 — intervention group
Group type: EXPERIMENTAL
Intervention: C7-T1 Maitland mobilization
Number of subjects: 42
Study 32762708 — intervention group
Group type: COMPARATOR
Intervention: Mid-thoracic (T3-T6) manipulation
Number of subjects: 42
Study 34779392 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patch with newly sourced adhesive component at end of shelf life (EOSL)
Number of subjects: 68
Study 34779392 — intervention group
Group type: COMPARATOR
Intervention: EVRA patch at beginning of shelf life (BOSL)
Number of subjects: 68
Study 34423501 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 plus Enzalutamide
Number of subjects: 47
Study 34423501 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide alone
Number of subjects: 47
Study 33350732 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based multimodal nursing program and routine nursing
Number of subjects: 0
Study 33350732 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 0
Study 34309426 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18-mg fluocinolone acetonide insert
Number of subjects: 129
Study 34309426 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 129
Study 32163038 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-based VR ACLS team leader refresher
Number of subjects: 25
Study 32163038 — intervention group
Group type: COMPARATOR
Intervention: HFS (high-fidelity simulation)
Number of subjects: 25
Study 35139273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (350 mg every 3 weeks)
Number of subjects: 608
Study 35139273 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of single-agent chemotherapy)
Number of subjects: 608
Study 34325519 — intervention group
Group type: EXPERIMENTAL
Intervention: Indexed minimal left atrial volume (LAVImin)
Number of subjects: 347
Study 34325519 — intervention group
Group type: COMPARATOR
Intervention: Indexed maximal left atrial volume
Number of subjects: 347
Study 34325519 — intervention group
Group type: EXPERIMENTAL
Intervention: LA emptying fraction and LA strain
Number of subjects: 347
Study 34617567 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 139
Study 34918632 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG) - participated in the entire curriculum training consisting of 48 different VR-simulator tasks over a continuous nine-day training session.
Number of subjects: 60
Study 34918632 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - performed two of the VR-simulator tasks on day 1 and 9.
Number of subjects: 60
Study 35915917 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson's Relaxation, performed twice a day for 10 minutes for 8 weeks after a training session
Number of subjects: 36
Study 35915917 — intervention group
Group type: COMPARATOR
Intervention: Educational session about Progressive Relaxation
Number of subjects: 36
Study 33450639 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention
Number of subjects: 56
Study 33450639 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 33450639 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 56
Study 33450639 — intervention group
Group type: EXPERIMENTAL
Intervention: Real World (RW)
Number of subjects: 56
Study 34415011 — intervention group
Group type: EXPERIMENTAL
Intervention: portion-controlled meals (PCM)
Number of subjects: 468
Study 34415011 — intervention group
Group type: EXPERIMENTAL
Intervention: acceptance-based treatment (ABT)
Number of subjects: 468
Study 34415011 — intervention group
Group type: EXPERIMENTAL
Intervention: Early TRA PCM
Number of subjects: 468
Study 34415011 — intervention group
Group type: COMPARATOR
Intervention: Late TRA PCM
Number of subjects: 468
Study 34375712 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT) with imbedded 10 Hz binaural beats combined with standard treatment
Number of subjects: 18
Study 34375712 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 18
Study 32839498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS)
Number of subjects: 7332
Study 32839498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for cancer-specific survival (CSS)
Number of subjects: 7332
Study 32839498 — intervention group
Group type: COMPARATOR
Intervention: Nomogram based on TNM stage
Number of subjects: 7332
Study 34009245 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32436800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-assisted postpartum family planning service (including contraceptive counselling and two reminders)
Number of subjects: 1000
Study 32436800 — intervention group
Group type: COMPARATOR
Intervention: Control group (received contraceptive counselling but no mobile phone reminders)
Number of subjects: 1000
Study 35331191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based self-help IMI
Number of subjects: 210
Study 35331191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)-based self-help IMI
Number of subjects: 210
Study 35331191 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 210
Study 32986271 — intervention group
Group type: EXPERIMENTAL
Intervention: Point transect method
Number of subjects: 7000
Study 32986271 — intervention group
Group type: COMPARATOR
Intervention: Traditional point-count method with fixed-radius listening areas
Number of subjects: 7000
Study 32986271 — intervention group
Group type: EXPERIMENTAL
Intervention: New method of analysis of singing probability per day (p[1])
Number of subjects: 7000
Study 34001070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal growth restriction
Number of subjects: 156
Study 34001070 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely low birth weight
Number of subjects: 156
Study 34001070 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding volume < 80 mL/kg/d at the end of the 4th week after birth
Number of subjects: 156
Study 34001070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestasis
Number of subjects: 156
Study 34001070 — intervention group
Group type: EXPERIMENTAL
Intervention: Late onset sepsis
Number of subjects: 156
Study 34001070 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged (> 2 weeks) diuretics application
Number of subjects: 156
Study 32674535 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength-oriented training group (STG)
Number of subjects: 30
Study 32674535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic training group (BTG)
Number of subjects: 30
Study 36113535 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal dexamethasone
Number of subjects: 2828
Study 36113535 — intervention group
Group type: COMPARATOR
Intervention: No intervention (placebo)
Number of subjects: 2828
Study 33214014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar Denervation (PD)
Number of subjects: 241
Study 33214014 — intervention group
Group type: COMPARATOR
Intervention: Non-Patellar Denervation (non-PD)
Number of subjects: 241
Study 33214014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PD and non-PD)
Number of subjects: 241
Study 33438732 — intervention group
Group type: EXPERIMENTAL
Intervention: M-system (endoscopic diagnostic process system)
Number of subjects: 16
Study 33438732 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with early differentiated carcinoma, undifferentiated carcinoma or inflammation)
Number of subjects: 16
Study 32485166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic habitats with bare soil
Number of subjects: 5123
Study 32485166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic habitats with culicine larvae
Number of subjects: 5123
Study 32485166 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly turbid habitats
Number of subjects: 5123
Study 32485166 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of predators in aquatic habitats
Number of subjects: 5123
Study 32873260 — intervention group
Group type: EXPERIMENTAL
Intervention: iPA (intervention targeting physical activity)
Number of subjects: 263
Study 32873260 — intervention group
Group type: EXPERIMENTAL
Intervention: iSED (intervention targeting sedentary behaviour)
Number of subjects: 263
Study 34290173 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone 40 mg
Number of subjects: 78
Study 34290173 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 2.5 mg
Number of subjects: 78
Study 36289300 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychobiotic diet (high in prebiotic and fermented foods)
Number of subjects: 45
Study 36289300 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 45
Study 36289300 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychobiotic diet
Number of subjects: 45
Study 34207080 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacutaneous Fibrolysis
Number of subjects: 66
Study 34207080 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 35285439 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 94
Study 35285439 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 94
Study 32729065 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional group (IPI monitor)
Number of subjects: 80
Study 32729065 — intervention group
Group type: COMPARATOR
Intervention: Control group (observational)
Number of subjects: 80
Study 32566130 — intervention group
Group type: EXPERIMENTAL
Intervention: Babble Boot Camp (BBC) intervention
Number of subjects: 5
Study 32566130 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (control)
Number of subjects: 5
Study 36441257 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost model
Number of subjects: 2469
Study 36441257 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression model
Number of subjects: 2469
Study 36441257 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine model
Number of subjects: 2469
Study 35776928 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel insertion of buddy anchor; 16.1 ± 1.8 cN·m insertion torque
Number of subjects: 24
Study 35776928 — intervention group
Group type: COMPARATOR
Intervention: Divergent insertion of buddy anchor; 12.0 ± 1.5 cN·m insertion torque
Number of subjects: 24
Study 32066534 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Ultra (Ultra)
Number of subjects: 1133
Study 32066534 — intervention group
Group type: COMPARATOR
Intervention: Xpert MTB/RIF (Xpert)
Number of subjects: 1133
Study 35060026 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced coagulation-flocculant process incorporating magnetic powder; 28.42 mg/L coagulant, 623 mg/L magnetic powder, 0.18 mg/L flocculant
Number of subjects: 0
Study 35060026 — intervention group
Group type: COMPARATOR
Intervention: Single RSM model
Number of subjects: 0
Study 35060026 — intervention group
Group type: COMPARATOR
Intervention: RSM-ANN model
Number of subjects: 0
Study 35060026 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated water
Number of subjects: 0
Study 33289602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate/Chondroitin Sulfate Preservative-free Ophthalmic Solution (SH/CS‐PF)
Number of subjects: 326
Study 33289602 — intervention group
Group type: COMPARATOR
Intervention: Systane® Ultra (PEG/PG)
Number of subjects: 326
Study 33289602 — intervention group
Group type: COMPARATOR
Intervention: Systane® Ultra PF (PEG/PG‐PF)
Number of subjects: 326
Study 35365187 — intervention group
Group type: EXPERIMENTAL
Intervention: Huzhang granules (HZG)
Number of subjects: 267
Study 35365187 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 267
Study 35365187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 36199177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek seed extract (5 cc) for 4 months
Number of subjects: 82
Study 32634642 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine + remifentanil
Number of subjects: 75
Study 32634642 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine + ½ remifentanil
Number of subjects: 75
Study 32634642 — intervention group
Group type: COMPARATOR
Intervention: remifentanil alone
Number of subjects: 75
Study 32634642 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study 35793878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral needling at CV 23, once a day for 5 days a week, for 4 courses (total duration not specified).
Number of subjects: 64
Study 35793878 — intervention group
Group type: COMPARATOR
Intervention: Swallowing rehabilitation training, once a day for 5 days a week, for 4 courses (total duration not specified).
Number of subjects: 64
Study 34116144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg intravenously on days 1 and 8, every 21 days
Number of subjects: 468
Study 34116144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 468
Study 34116144 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy treatment of physician's choice (TPC)
Number of subjects: 468
Study 33136751 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV)
Number of subjects: 591
Study 33136751 — intervention group
Group type: COMPARATOR
Intervention: Current antiretroviral regimen (CAR)
Number of subjects: 591
Study 35108307 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing available
Number of subjects: 1194
Study 35108307 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive test result
Number of subjects: 1194
Study 35108307 — intervention group
Group type: COMPARATOR
Intervention: No testing available
Number of subjects: 1194
Study 32652899 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum myostatin expression in T1D patients
Number of subjects: 55
Study 32652899 — intervention group
Group type: COMPARATOR
Intervention: Serum myostatin expression in controls
Number of subjects: 55
Study 32652899 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean mass correlation
Number of subjects: 55
Study 32652899 — intervention group
Group type: COMPARATOR
Intervention: Maximal voluntary contraction (MVC) correlation
Number of subjects: 55
Study 32652899 — intervention group
Group type: COMPARATOR
Intervention: Body fat mass correlation
Number of subjects: 55
Study 36372355 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus Carfilzomib and Dexamethasone (Isa-Kd)
Number of subjects: 302
Study 33140886 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid receptor antagonist naltrexone
Number of subjects: 42
Study 33140886 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert substance)
Number of subjects: 42
Study 35441795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent solution with ropivacaine
Number of subjects: 314
Study 35441795 — intervention group
Group type: COMPARATOR
Intervention: Tumescent solution without ropivacaine
Number of subjects: 314
Study 35441795 — intervention group
Group type: COMPARATOR
Intervention: Tumescent solution with/without ropivacaine (inter-group comparison)
Number of subjects: 314
Study 33780271 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session solution-oriented goal-setting program
Number of subjects: 52
Study 33780271 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 52
Study 32690072 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (starting dose 5 mg daily, maximum 20 mg daily)
Number of subjects: 58
Study 32690072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32690072 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 58
Study 35606099 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 36
Study 35606099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity group intervention
Number of subjects: 36
Study 35606099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 34302571 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with Azospirillum brasilense
Number of subjects: 4
Study 34302571 — intervention group
Group type: COMPARATOR
Intervention: Control (no inoculation with A. brasilense)
Number of subjects: 4
Study 35068328 — intervention group
Group type: COMPARATOR
Intervention: Abdominopelvic exercise program (AEP)
Number of subjects: 47
Study 35068328 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominopelvic exercise program with postural instructions (AEPPI)
Number of subjects: 47
Study 33545781 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort care based on the collaborative care model (CCM)
Number of subjects: 104
Study 33545781 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 104
Study 32708743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation including prebiotics and probiotics for four weeks
Number of subjects: 22
Study 32708743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 35238494 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT + KinesioTaping
Number of subjects: 25
Study 35238494 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT + ShamTaping
Number of subjects: 25
Study 35238494 — intervention group
Group type: COMPARATOR
Intervention: BoNT
Number of subjects: 25
Study 32583707 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (triweekly for 12 weeks)
Number of subjects: 22
Study 33588590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Thrombolysis (IVT)
Number of subjects: 220
Study 33588590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 33105360 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) in multijoint to single-joint order (MJ-SJ)
Number of subjects: 44
Study 33105360 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) in single-joint to multijoint order (SJ-MJ)
Number of subjects: 44
Study 33105360 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group (CON)
Number of subjects: 44
Study 36163903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg QD (PACE)
Number of subjects: 364
Study 36163903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg QD (OPTIC)
Number of subjects: 364
Study 36163903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (PACE)
Number of subjects: 364
Study 36163903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib (OPTIC)
Number of subjects: 364
Study 33999133 — intervention group
Group type: EXPERIMENTAL
Intervention: This is Quitting, a fully automated text message program for vaping cessation that delivers social support and cognitive and behavioral coping skills training.
Number of subjects: 2588
Study 33999133 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (no additional intervention).
Number of subjects: 2588
Study 33999133 — intervention group
Group type: EXPERIMENTAL
Intervention: This is Quitting intervention.
Number of subjects: 2588
Study 35078532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing dogs
Number of subjects: 0